No Data
2024 ANNUAL REPORT
2024 Annual Report Summary
Tianxin Pharmaceutical (603235.SH): The net income for 2024 is expected to grow by 36.85% year-on-year, proposing a dividend of 0.68 yuan per share.
On April 25, Gelonghui reported that Tianxin Pharmaceutical (603235.SH) published its annual report for 2024. During the reporting period, the company achieved revenue of 2,208.5702 million yuan, an increase of 17.35% compared to the same period last year; the net income attributable to shareholders of the listed company was 651.2231 million yuan, an increase of 36.85% compared to the same period last year. The company plans to distribute a cash dividend of 0.68 yuan per share to all shareholders.
Tianxin Pharmaceutical (603235.SH): The actual controller and Director XU Jiangnan has lifted the detention.
On March 27, Gelonghui reported that Tianxin Pharmaceutical (603235.SH) announced that on November 2, 2024, it disclosed the 'Announcement on the Actual Controller and Chairman Being Detained.' The actual controller and Chairman Mr. Xu Jiangnan was detained and investigated by the Dongning City Supervisory Committee. On March 27, 2025, the company received the 'Notice of Lifting Detention' issued by the Dongning City Supervisory Committee, deciding to lift the detention measures on Mr. Xu Jiangnan. Currently, Mr. Xu Jiangnan can perform his duties as the Chairman of the company normally, and the company's production and operation situation is normal.
JiangXi Tianxin Pharmaceutical Co., Ltd.'s (SHSE:603235) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Is JiangXi Tianxin Pharmaceutical (SHSE:603235) A Risky Investment?
